Shares of Aurobindo Pharma Ltd rose 1% to touch a day’s high of Rs 1,210 on 2nd January. This happened after the company said its wholly owned arm, Auro Pharma Ltd, has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories Private Ltd on a going-concern basis. The all-cash transaction is valued at Rs 325 cr.

The acquisition was completed through a Business Transfer Agreement (BTA) and is effective from 1st January 2026. This information comes from the company’s exchange filing.

The deal includes 23 brands across 67 SKUs, along with nine pipeline products. These are mainly focused on anti-infective and pain management therapies.

The acquired business has a strong on-ground presence. It employs around 470 field staff and is supported by a distribution network of over 1,600 stockists.

In FY2024–25, the non-oncology prescription business reported a turnover of Rs 1,135.3 million. It reported an EBITDA of Rs 289.9 million, as per the filing.

Founded in 1973–74, Khandelwal Laboratories operates in India and specialises in both oncology and non-oncology branded prescription formulations.

Auro Pharma said the acquisition will strengthen its domestic market presence. It will also enhance growth prospects and expand its prescription offerings, especially in pain management and anti-infective segments.

At 11:50 AM, shares of Aurobindo Pharma were trading 1.47% higher at Rs 1,210.50 on NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!